| Literature DB >> 33317533 |
Ryota Dokuni1, Tatsuya Nagano2, Naoe Jimbo3, Hiroki Sato1, Tatsunori Kiriu1, Yuichiro Yasuda1, Masatsugu Yamamoto1, Motoko Tachihara1, Kazuyuki Kobayashi1, Yoshimasa Maniwa4, Yoshihiro Nishimura1.
Abstract
BACKGROUND: Recent studies have revealed that serpin peptidase inhibitor clade E member 2 (SERPINE2) is associated with tumorigenesis. However, SERPINE2 expression and its role in lung adenocarcinomas are still unknown.Entities:
Keywords: Adenocarcinoma; Lung cancer; Serpin peptidase inhibitor clade E member 2
Year: 2020 PMID: 33317533 PMCID: PMC7737331 DOI: 10.1186/s12931-020-01597-5
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Fig. 1Microscopic images of spiral array specimens. Low power fields of a H&E staining, c SERPINE2 positive staining, and e SERPINE2 negative staining and high power fields of b H&E staining, d SERPINE2 positive staining, and f SERPINE2 negative staining are shown
Patient characteristics
| SERPINE2 | High | Low | P value |
|---|---|---|---|
| Number of case | 19 | 55 | |
| Age [median (range)] | 69 (54–83) | 72 (49–85) | |
| Male | 13 | 28 | 0.284 |
| Smoking history | 14 | 30 | 0.181 |
| Lobectomy | 16 | 40 | 0.372 |
| Partial resection | 3 | 15 | |
| pT1 | 10 | 26 | 0.847 |
| pT2 | 9 | 28 | |
| pT3 | 0 | 1 | |
| pN0 | 16 | 43 | 0.121 |
| pN1 | 0 | 8 | |
| pN2 | 3 | 4 | |
| pM0 | 19 | 55 | |
| Pleural invasion | 8 | 19 | 0.589 |
| Lymphatic invasion | 10 | 12 | 0.0188 |
| Vascular invasion | 9 | 20 | 0.425 |
| pStage IA | 11 | 25 | 0.163 |
| pStage IB | 5 | 13 | |
| pStage IIA | 0 | 11 | |
| pStage IIB | 0 | 2 | |
| pStage IIIA | 3 | 4 | |
| R0 | 19 | 55 | |
| EGFR mutation | |||
| Ex21 L858R | 5 | 7 | 0.416 |
| Ex19 del | 1 | 4 | |
| Negative | 9 | 23 | |
| Unknown | 12 | 13 | |
| Adjuvant chemotherapy | 4 | 19 | 0.391 |
Fisher’s exact test
Fig. 2Kaplan–Meier survival curve. High SERPINE2 expression is correlated with poor prognosis
Univariate analysis
| Variables | Cut off | Hazard ratio | 95% CI for HR | P value |
|---|---|---|---|---|
| pT factor | < 2 vs. ≥ 2 | 3.08 | 0.596–15.91 | 0.1795 |
| pN factor | 0 vs. ≥ 1 | 2.787 | 0.6227–12.48 | 0.1801 |
| Lymphatic invasion | 0 vs. 1 | 2.375 | 0.5291–10.66 | 0.93750 |
| Pleural invasion | 0 vs. ≥ 1 | 3.383 | 0.7553–15.15 | 0.1111 |
| Vascular invasion | 0 vs. 1 | 2.623 | 0.5863–11.73 | 0.2072 |
| SERPINE2 | Low vs. high | 5.273 | 1.151–24.16 | 0.03228 |
Multivariate analysis
| Variables | Cut off | Hazard ratio | 95% CI for HR | P value |
|---|---|---|---|---|
| pT factor | < 2 vs. ≥ 2 | 2.2610 | 0.13140–38.900 | 0.57420 |
| pN factor | 0 vs. ≥ 1 | 3.5320 | 0.34880–35.770 | 0.28540 |
| Lymphatic invasion | 0 vs. 1 | 0.4981 | 0.06594–3.763 | 0.49940 |
| Pleural invasion | 0 vs. ≥ 1 | 0.6023 | 0.04930–7.358 | 0.69130 |
| Vascular invasion | 0 vs. 1 | 2.8550 | 0.31770–25.650 | 0.34910 |
| SERPINE2 | Low vs. high | 9.0520 | 1.20300–68.090 | 0.03237 |
Fig. 3Survival analysis in TCGA dataset. The survival analysis based on TCGA dataset (LUAD) is shown
Fig. 4SERPINE2 expression and knockdown effect of SERPINE2. a SERPINE2 expression in lung cancer cell lines was normalized to BEAS-2B. b, c The efficacies of siRNA in A549 and PC9 cells were analyzed by qRT-PCR (B, relative to negative control) and western blotting (c). nc, negative control; #1, siRNA#1; #2, siRNA#2
Fig. 5Effect of SERPINE2 knockdown on cell number. The results of the cell number assay are shown. nc, negative control; #1, siRNA#1; #2, siRNA#2
Fig. 6Effect of SERPINE2 knockdown on apoptosis. Western blotting analysis of apoptosis-related proteins at the indicated time points after Fas ligand stimulation is shown. A549 (upper) and PC9 (lower) cells pretreated with SERPINE2 siRNA were stimulated with Fas ligand (200 ng/ml). nc, negative control; #2, siRNA#2